Serum level of miR-10-5p as a prognostic biomarker for acute myeloid leukemia

Zhi, Yongjin; Xie, Xian-Jin; Wang, Rong; Wang, Biao; Gu, Weiying; Ling, Yun; Dong, Weimin; Zhi, Feng; Liu, Yan

doi:10.1007/s12185-015-1829-6

Cited by 41 publications

(29 citation statements)

References 41 publications

(51 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In agreement with the observations of the present study, the expression levels of miR-10a-5p in tumor FFPE samples were demonstrated to be >2-fold higher in progession-free patients compared with patients with progressive disease in bladder cancers (21). The prognostic significance of miR-10a-5p was also confirmed in acute myeloid leukemia, where the serum expression levels of this miRNA were significantly higher in comparison with a control group (22). In patients with recurrent platinum-resistant ovarian cancer, higher expression levels of miR-10a-5p were noted in peripheral blood plasma and associated with a sensitivity to decitabine followed by carboplatin chemotherapy (23).…”

Section: Discussionmentioning

confidence: 72%

MicroRNAs as outcome predictors in patients with metastatic colorectal cancer treated with bevacizumab in combination with FOLFOX

et al. 2017

View full text Add to dashboard Cite

Bevacizumab is a humanized anti-vascular endothelial growth factor monoclonal antibody, used in combination with a oxaliplatin-based chemotherapy in the treatment of metastatic colorectal cancer (mCRC). The aim of the present study was to identify microRNA (miRNA)-based predictive biomarkers of therapy response in order to avoid unnecessary and costly therapy to non-responding patients. High-throughput miRNA microarray profiling (Affymetrix miRNA array) was performed on a discovery cohort of patients with mCRC. The discovery cohort was (n=20) divided into either responding (n=10) or non-responding (n=10) groups of bevacizumab/5-flourouracil, leucovorin, oxaliplatin (FOLFOX) treatment according to Response Evaluation Criteria in Solid Tumors criteria. Validation of candidate miRNAs was performed on an independent cohort of 41 patients with mCRC using quantitative reverse transcription polymerase chain reaction. Normalized data were subjected to receiver operating characteristic and Kaplan-Meier analyses. In total, 67 miRNAs were identified to be differentially expressed when miRNA expression was compared between responding and non-responding patients to bevacizumab/FOLFOX treatment (P<0.05). A total of 7 miRNAs were chosen for independent validation, which confirmed significantly higher expression of miR-92b-3p, miR-3156-5p, miR-10a-5p and miR-125a-5p (P<0.005) in tumor tissue of responding patients compared with non-reponding patients. Using the combination of miRNAs, the present study identified responders to the therapy with sensitivity 82% and specificity 64% (area under the curve = 0.8015). In conclusion, 4 predictive miRNAs associated with progression-free survival (PFS) were identified in patients with mCRC treated with bevacizumab/FOLFOX. Following further independent validations, detection of these miRNA may enable identification of patients with mCRC who may potentially benefit from the therapy.

show abstract

Section: Discussionmentioning

confidence: 72%

MicroRNAs as outcome predictors in patients with metastatic colorectal cancer treated with bevacizumab in combination with FOLFOX

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Therefor monitoring of particular miRNA expression profiles from diagnosis and during follow-up of patients can add to the evaluation of result and assurance of relapse and prescient biomarkers of forecast in leukemic patients (Hajizamani, Shahjahani, Shahrabi, & Saki, 2017; Table 3). Zhi, Xie, et al (2015); Y. MiR-223…”

Section: Mirna As a Diagnostic And Prognostic Biomarkermentioning

confidence: 99%

MicroRNA in leukemia: Tumor suppressors and oncogenes with prognostic potential

Mardani

Abadi

Motieian

et al. 2018

Journal Cellular Physiology

View full text Add to dashboard Cite

Leukemia is known as a progressive malignant disease, which destroys the blood‐forming organs and results in adverse effects on the proliferation and development of leukocytes and their precursors in the blood and bone marrow. There are four main classes of leukemia including acute leukemia, chronic leukemia, myelogenous leukemia, and lymphocytic leukemia. Given that a variety of internal and external factors could be associated with the initiation and progression of different types of leukemia. One of the important factors is epigenetic regulators such as microRNAs (miRNAs) and long noncoding RNAs (ncRNA). MiRNAs are short ncRNAs which act as tumor suppressor (i.e., miR‐15, miR‐16, let‐7, and miR‐127) or oncogene (i.e., miR‐155, miR‐17‐92, miR‐21, miR‐125b, miR‐93, miR‐143‐p3, miR‐196b, and miR‐223) in leukemia. It has been shown that deregulation of these molecules are associated with the initiation and progression of leukemia. Hence, miRNAs could be used as potential therapeutic candidates in the treatment of patients with leukemia. Moreover, increasing evidence revealed that miRNAs could be used as diagnostic and prognostic biomarkers in monitoring patients in early stages of disease or after received chemotherapy regimen. It seems that identification and development of new miRNAs could pave to the way to the development new therapeutic platforms for patients with leukemia. Here, we summarized various miRNAs as tumor suppressor and oncogene which could be introduced as therapeutic targets in treatment of leukemia.

show abstract

“…In previous reports, these microRNAs were shown to have important tumor-promoting properties. For example, overexpression of miR - 10a was associated with poor OS in AML patients [26]. Up-regulation of miR - 155 was an independent risk factor associated with an unfavorable clinical outcome in cytogenetically normal-AML (CN-AML) [3].…”

Section: Resultsmentioning

confidence: 99%

High expression of ETS2 predicts poor prognosis in acute myeloid leukemia and may guide treatment decisions

et al. 2017

J Transl Med

View full text Add to dashboard Cite

Background ETS2 is a downstream effector of the RAS/RAF/ERK pathway, which plays a critical role in the development of malignant tumor. However, the clinical impact of ETS2 expression in AML remains unknown. MethodsIn this study, we evaluated the prognostic significance of ETS2 expression using two relatively large cohorts of AML patients.ResultsIn the first cohort, compared to low expression of ETS2 (ETS2 low), high expression of ETS2 (ETS2 high) showed significant shorter OS, EFS and RFS in the current treatments including the allogeneic HCT group (n = 72) and the chemotherapy group (n = 100). Notably, among ETS2 high patients, those received allogeneic HCT had longer OS, EFS and RFS than those with chemotherapy alone (allogeneic HCT, n = 39 vs. chemotherapy, n = 47), but treatment modules play insignificant role in the survival of ETS2 low patients (allogeneic HCT, n = 33 vs. chemotherapy, n = 53). Moreover, gene/microRNA expression data provides insights into the biological changes associated with varying ETS2 expression levels in AML. The prognostic value of ETS2 was further validated in the second AML cohort (n = 329).ConclusionsOur results indicate that ETS2 high is a poor prognostic factor in AML and may guide treatment decisions towards allogeneic HCT.Electronic supplementary materialThe online version of this article (doi:10.1186/s12967-017-1260-2) contains supplementary material, which is available to authorized users.

show abstract

Serum level of miR-10-5p as a prognostic biomarker for acute myeloid leukemia

Cited by 41 publications

References 41 publications

MicroRNAs as outcome predictors in patients with metastatic colorectal cancer treated with bevacizumab in combination with FOLFOX

MicroRNAs as outcome predictors in patients with metastatic colorectal cancer treated with bevacizumab in combination with FOLFOX

MicroRNA in leukemia: Tumor suppressors and oncogenes with prognostic potential

High expression of ETS2 predicts poor prognosis in acute myeloid leukemia and may guide treatment decisions

Contact Info

Product

Resources

About